Elixir Pharmaceuticals

company

About

Elixir Pharmaceuticals develops and commercializes pharmaceuticals for the treatment of metabolic diseases.

  • 11 - 50

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$15M
Industries
Biotechnology,Diabetes,Pharmaceutical
Founded date
Jan 1, 1999
Number Of Employee
11 - 50
Operating Status
Active

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$98.50M
Elixir Pharmaceuticals has raised a total of $98.50M in funding over 2 rounds. Their latest funding was raised on May 19, 2009 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 19, 2009 Series D $12M 1 Detail
Nov 27, 2006 Debt Financing $15M 1 Detail
Nov 27, 2006 Series C $31M 2 Detail
Oct 13, 2003 Series B $40.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Elixir Pharmaceuticals is funded by 2 investors. ARCH Venture Partners and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series D
Hercules Capital Debt Financing